PT - JOURNAL ARTICLE AU - Shen, Yanhan AU - Franks, Julie AU - Reidy, William AU - Olsen, Halli AU - Wang, Chunhui AU - Mushimbele, Nadine AU - Mazala, Richted Tenda AU - Tchissambou, Tania AU - Malele, Faustin AU - Kilundu, Apolinaire AU - Bingham, Trista AU - Djomand, Gaston AU - Mukinda, Elie AU - Ewetola, Raimi AU - Abrams, Elaine J. AU - Teasdale, Chloe A. TI - Pre-exposure Prophylaxis Uptake Concerns in the Democratic Republic of the Congo: Key Population and Healthcare Workers Perspectives AID - 10.1101/2023.01.13.23284513 DP - 2023 Jan 01 TA - medRxiv PG - 2023.01.13.23284513 4099 - http://medrxiv.org/content/early/2023/01/17/2023.01.13.23284513.short 4100 - http://medrxiv.org/content/early/2023/01/17/2023.01.13.23284513.full AB - Key populations (KP) in the Democratic Republic of the Congo (DRC), including female sex workers (FSW), are disproportionally affected by HIV. Quantitative feedback surveys were conducted at seven health facilities in DRC with 70 KP clients enrolled in services to measure pre-exposure prophylaxis (PrEP) benefits and concerns. The surveys also assessed satisfaction with PrEP services and experiences of stigma at the health facilities. Thirty healthcare workers (HCW) were surveyed to measure attitudes, beliefs, and acceptability of providing services to KP. KP client survey participants were primarily female SW. KP clients reported that the primary concern about taking PrEP was fear of side effects. HCW concurred with clients that experienced and anticipated side effects were a primary PrEP uptake concern, along with costs of clinic visits.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the President’s Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC) under the terms of Cooperative Agreement Numbers U2GGH000994. JF, WR, HO, CW, NM, RTM, TT, FM, EAJ and CAT received funding for this work. TB, GD, EM and RE are employees of the CDC who, as the funder, contribute to study design and manuscript development but did not have access to participant information or study data.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:DRC Ministry of Public Health’s National Ethics Committee for Health Columbia University Irving Medical Center Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe study includes data abstracted from medical charts, therefore, the study data belong to the government of DRC so cannot be made publicly available for download. The data can be shared when requested, inquiries should be sent to icap{at}columbia.edu